AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
61.80
+0.30 (0.49%)
Apr 28, 2026, 1:55 PM CST
188.79%
Market Cap 5.81B
Revenue (ttm) 7.55M
Net Income (ttm) -357.87M
Shares Out 94.06M
EPS (ttm) -3.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 165,040
Average Volume 299,632
Open 62.00
Previous Close 61.50
Day's Range 60.80 - 62.00
52-Week Range 21.20 - 69.90
Beta n/a
RSI 47.38
Earnings Date Aug 12, 2026

About AnnJi Pharmaceutical

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7754
Full Company Profile

Financial Performance

In 2025, AnnJi Pharmaceutical's revenue was 7.55 million, a decrease of -92.17% compared to the previous year's 96.45 million. Losses were -357.87 million, 1.10% more than in 2024.

Financial Statements

News

There is no news available yet.